London Stock Exchange today welcomes GENinCode plc (“GENinCode” or the “Company” with the LSE-AIM ticker “GENI”), the cardiovascular disease (“CVD”) risk assessment company focused on predictive genetics for the prevention of cardiovascular disease. The Company is incorporated in England and Wales with its UK headquarters in Oxford. 

The Company has successfully raised £17 million in total on 13 July 2021, which includes the proceeds from the Placing and Subscription. The Company’s market capitalisation is approximately £42 million on admission with a free float of 37.95%. 

GENinCode specialises in the risk assessment and prediction of cardiovascular disease, thrombosis and familial hypercholesterolemia. CVD is a broad disease classification including coronary artery disease and myocardial infarction often referred to as ‘heart attack’. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for nearly a third of all deaths in the United States.

The Company and management team is passionate about the advance of genetics in personalised medicine and are committed to driving and supporting the incorporation of genetics in daily medical practice, through cooperation with health care professionals to improve the management of patient health in the areas of primary preventative care, diagnosis, and treatment.

The Company’s genomic technology and products have been fully validated over the past 10 years by significant international scientific and clinical evidence. From offices based in the UK, US and EU, GENinCode provide doctors and health care practitioners with precise personalised health information which combines traditional clinical measures with a patient’s genetic information to deliver comprehensive CVD risk assessment and improved clinical recommendations. GENinCode’s products help educate patients of their cardiovascular risk and support their adherence to therapy to improve health outcomes. 

Matthew Walls, Chief Executive Officer of GENinCode, said: “I am delighted with the level of interest and strong support generated from new institutional investors ahead of our admission to trading on AIM. The additional funds raised will allow us to further exploit the significant market opportunity to deliver clinically proven genomic precision testing products for the CVD market. 

“We want to improve the current standard of care and enhance the assessment of the risk of the onset of CVD in what is globally the leading cause of death. CVD accounts for over 17.9 million deaths annually, representing approximately 31 per cent. of all deaths worldwide with the global cost of CVD estimated to reach approximately $1.04 trillion by 2030.”

To find out more about GENinCode Plc, please contact: 

GENinCode plc   - www.genincode.com - Via Walbrook PR

Matthew Walls, CEO    
Paul Foulger, CFO    
    
Stifel Nicolaus Europe Limited (Nomad and Joint Broker)    Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short    
    
Cenkos Securities Plc (Joint Broker)    Tel: +44 (0)20 7397 8900
Giles Balleny     
Dale Bellis / Michael Johnson (Sales)        
    
Walbrook PR Limited     Tel: 020 7933 8780 or genincode@walbrookpr.com 

Anna Dunphy / Paul McManus / Louis Ashe-Jepson    

Board of Directors

William Edward Rhodes – Independent Non-Executive Chairman (age 67)
Matthew Walls – Chief Executive Officer (age 57)
Paul Andrew Peter Foulger – Chief Financial Officer (age 51)
Jordi Puig Gilberte – Founder and Chief Operations Officer (age 46)
David Eric Evans – Independent Non-Executive Director (age 61)
Sergio Olivero Rigau – Non-Executive Director (age 59)

Significant shareholders – Pre / Post-IPO

¹Jordi Puig and Sonia Rodriguez Clemente are husband and wife and together will hold 15.11% of the issued share capital of the Company on Admission
² Jordi Puig has the benefit of a call option over Sergio Oliveró's shares representing an additional 3.73 per cent. of the Enlarged Share Capital of the Company
³ held via Maven Income and Growth VCT plc, Maven Income and Growth VCT 3 plc, Maven Income and Growth VCT 4 plc and Maven Income and Growth VCT 5 plc
⁴ held via Downing 1 VCT plc and Downing 4 VCT plc
 

Advisors

Stifel Nicolaus Europe Limited – Nominated adviser, Sole Global Coordinator and Joint Bookrunner
Cenkos Securities plc – Joint Bookrunner
Crowe U.K. LLP – Reporting Accountant
Jeffreys Henry LLP – Auditor
Addleshaw Goddard LLP – Solicitors to the Company
Fieldfisher LLP – Solicitor to the Nominated Adviser and Joint Bookrunners
Walbrook PR Ltd – Financial Public Relations Adviser
Link Asset Services - Registrars